Experimental Chemotherapy of Mycobacterial Diseases

  • Jacques Grosset
  • Baohong Ji
Chapter
Part of the Chapman & Hall Medical Microbiology Series book series (CHMMS)

Abstract

Experimental chemotherapy of tuberculois provides the opportunity to assess, in vivo, the antimicrobial activity of a newly developed drug in comparison with that of existing drugs, its antagonistic, additional, or synergistic activity when it is given in combination with other drugs, its ability to prevent the selection of mutants resistant to the other drugs, and, finally, its ability to sterilize the lesions of the experimentally infected animals. However, to obtain reliable information, experimental chemotherapy should be performed in an adequate model. Because of its exquisite susceptibility to Mycobacterium tuberculosis infection, the guinea pig has been long been the animal of choice for detecting the presence of a tiny number of tubercle bacilli in a clinical specimen. It has also been used in experiments to assess the airborne transmission of tuberculosis and the impact of chemotherapy on the transmission (1), the comparative virulence of different strains of M. tuberculosis (2), the protective value of M. bovis Bacille—Calmette—Guérin (BCG) against a subsequent challenge with M. tuberculosis (3), and the comparative antituberculosis activity of several drugs and drug combinations given daily or intermittently (4,5). In spite of its numerous advantages, the guinea pig has not been used extensively as an animal model for the experimental chemotherapy of tuberculosis because its size makes it difficult to be used in large numbers, its metabolism is different from that of humans, and, finally, it has a high sensitivity to intercurrent infections.

Keywords

Antimicrob Agent Mycobacterium Avium Mycobacterium Avium Complex Antituberculosis Drug Mycobacterial Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Grady F, Riley RL (1963) Experimental airborne tuberculosis. Adv Tuberc Res 12:150–190.Google Scholar
  2. 2.
    Mitchison DA, Wallace JG, Bhatia AL, Selkon JB, Subbaiah TV, Lancaster MC (1960) A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. Tubercle 41:1–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith DW (1985) Protective effect of BCG in experimental tuberculosis. Adv Tuberc Res 22:1–99.PubMedGoogle Scholar
  4. 4.
    Dickinson JM, Mitchison DA (1970) Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 51:82–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Dickinson JM, Mitchison DA (1976) Bactericidal activity in vitro and in the guineapig of isoniazid, rifampicin and ethambutol. Tubercle 57:251–258.PubMedCrossRefGoogle Scholar
  6. 6.
    Dannenberg AM Jr. (1994) Rabbit model of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control, pp. 149–156. Washington, DC: American Society for Microbiology.Google Scholar
  7. 7.
    Good RC (1994) Diseases in nonhuman primates. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Source Book, pp. 903–924. New York: Marcel Dekker, Inc.Google Scholar
  8. 8.
    Lurie MB (1964) Resistance to Tuberculosis: Experimental Studies in Native and Acquired Defensive Mechanisms. Cambridge, MA: Harvard University Press.Google Scholar
  9. 9.
    Raleigh GW, Youmans GP (1948) The use of mice in experimental chemotherapy of tuberculosis. I. Rationale and review of literature. J Infect Dis 82:197–204.PubMedCrossRefGoogle Scholar
  10. 10.
    Pierce SH, Dubos RJ, Schaefer WB (1953) Multiplication and survival of tubercle bacilli in the organs of mice. J Exp Med 97:189–205.PubMedCrossRefGoogle Scholar
  11. 11.
    Youmans GP, Youmans AS (1964) Experimental chemotherapy of tuberculosis and other mycobacterial infections. In: Schnitzer RJ, Hawking F, eds. Experimental Chemotherapy. Vol. II, pp. 393–499. New York: Academic Press.Google Scholar
  12. 12.
    Grumbach F (1965) Etudes chimiothérapiques sur la tuberculose avancée de la souris. Adv Tuberc Res 14:31–96.Google Scholar
  13. 13.
    Lefford MJ (1984) Diseases in mice and rats. In: Kubica GP, Wayne LG, eds. The Mycobacteria: A Source Book, pp. 947–977. New York: Marcel Dekker, Inc.Google Scholar
  14. 14.
    Lecoeur HF, Lagrange Ph, Truffot-Pernot Ch, Gheorghiu M, Grosset J (1989) Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 76:458–462.PubMedGoogle Scholar
  15. 15.
    Chapuis L, Ji B, Truffot-Pernot C, O’Brien RJ, Raviglione MC, Grosset JH (1994) Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Unit Care Med 150:1355–1362.Google Scholar
  16. 16.
    Fenner F (1951) The enumeration of viable tubercle bacilli by surface plate counts. Am Rev Tuberc 64:353–380.PubMedGoogle Scholar
  17. 17.
    Grosset J, Truffot-Pemot C, Lacroix C, Ji B (1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36:548–551.PubMedCrossRefGoogle Scholar
  18. 18.
    Truffot-Pernot C, Ji B, Grosset J (1991) Activities of pefloxacin and ofloxacin against Mycobacteria: in vivo and mouse experiments. Tubercle 72:57–64.PubMedCrossRefGoogle Scholar
  19. 19.
    Grosset J (1978) The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 53:5–12.PubMedGoogle Scholar
  20. 20.
    Dickinson JM, Mitchison DA (1991) Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. Tubercle 72:110–114.PubMedCrossRefGoogle Scholar
  21. 21.
    Lalande V, Truffot-Pemot C, Paccaly-Moulin A, Grosset J, Ji B (1993) Powerful bactericidal activity of sparfloxacin (AT-4140) against M. tuberculosis in mice. Antimicrob Agents Chemother 37: 407–413.PubMedCrossRefGoogle Scholar
  22. 22.
    Dubos RJ, Middlebrook G (1947) Media for tubercle bacilli. Am Rev Tuberc 56:334–345.PubMedGoogle Scholar
  23. 23.
    Orme IM, Collins FM (1994) Mouse model of tuberculosis. In: Bloom BR, ed., Tuberculosis: Pathogenesis, Protection, and Control, pp. 113–134. Washington, DC: American Society for Microbiology.Google Scholar
  24. 24.
    Lecoeur HF, Truffot-Pernot C, Grosset JH (1989) Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140:1189–1193.PubMedCrossRefGoogle Scholar
  25. 25.
    Rowland M, Tozer TN (1980) Clinical pharmacokinetics, concepts and applications. Philadelphia: Lea & Febriger.Google Scholar
  26. 26.
    Hooper DC, Wolfson JS (1985) The fluoroquinolones: pharmacology, clinical uses, and toxicities. Antimicrob Agents Chemother 28:716–721.PubMedCrossRefGoogle Scholar
  27. 27.
    Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O’Brien RJ, O11iaro P, Roscigno G, Grosset J (1993) Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 148:1541–1546.PubMedCrossRefGoogle Scholar
  28. 28.
    Barkley WE, Kubica GP (1994) Biological safety in the experimental tuberculosis laboratory. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection and Control, pp. 61–71. Washington, DC: American Society for Microbiology.Google Scholar
  29. 29.
    Ji B, Truffot-Pernot C, Grosset J (1991) In vitro and in vivo activities of sparfoxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72: 181–186.PubMedCrossRefGoogle Scholar
  30. 30.
    Grosset J (1980) Bacteriologic basis of short-course chemotherapy for tuberculosis Clinics. Chest Med 1:231–141.Google Scholar
  31. 31.
    Canetti G, Grumbach F, Grosset J (1960) Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid. Am Rev Respir Dis 82:295–313.PubMedGoogle Scholar
  32. 32.
    Flor SC, Rogge MC, Chow AT (1993) Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Antimicrob Agents Chemother 37:1468–1472.PubMedCrossRefGoogle Scholar
  33. 33.
    Israel D, Gillum JG, Turik M, Harvey K, Ford J, Dalton H, Towle M, Echols R, Heller A, Polk R (1993) Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents chemother 37:2193–2199.PubMedCrossRefGoogle Scholar
  34. 34.
    McDermott W (1958) Microbial persistence. Yale J Biol Med 30:257–291.PubMedGoogle Scholar
  35. 35.
    McCune RM Jr, Tompsett R (1956) Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistance of drug susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 104:737–762.PubMedCrossRefGoogle Scholar
  36. 36.
    McCune RM Jr, Tompsett R, McDermott W. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculosis infection to the latent state by the administration of PZA and a companion drug. J Exp Med 104:763–802.Google Scholar
  37. 37.
    Grosset J, Grumbach F, Rist N (1978) Le rôle de la rifampicine dans la phase ultime du traitement de la tuberculose murine expérimentale. Rev Fr Mal Respir 6:515–520.Google Scholar
  38. 38.
    Medical Research Council Investigation (1948) Streptomycin treatment of pulmonary tuberculosis. Br Med J 2:769–782.CrossRefGoogle Scholar
  39. 39.
    Medical Research Council Investigation (1950) Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. Br Med J 2:1073–1086.CrossRefGoogle Scholar
  40. 40.
    Schatz A, Bugie E, Wasksman SA (1994) Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med 55:66–69.Google Scholar
  41. 41.
    Lehmann J (1946) Para-aminosalicylic acid in the treatment of tuberculosis. Lancet I:15–16.CrossRefGoogle Scholar
  42. 42.
    Bernstein J, Lott WA, Steinberg BA, Yale HL (1952) Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (Nidrazid) and related compounds. Am Rev Tuberc 65:357–364.PubMedGoogle Scholar
  43. 43.
    Grünberg E, Schnitzer RJ (1952) Studies on the activity of hydrazine derivatives of isonicotinic acid in experimental tuberculosis of mice. Quart Bull Seaview Hosp 13:3–11.Google Scholar
  44. 44.
    Füresz S, Arioli V, Pallanza R (1965) Antimicrobial properties of new derivatives of rifamycin SV. Antimicrob Agents Chemother 4:770–774.Google Scholar
  45. 45.
    Grumbach F, Canetti G, Grosset J, Le Lirzin M (1967) Late results of long-term, intermittent chemotherapy of advanced murine tuberculosis: Limits of the murine model. Tubercle 48:11–26.PubMedCrossRefGoogle Scholar
  46. 46.
    Medical Research Council/Tuberculosis Chemotherapy Trials Committee (1962) Long-term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. Tubercle 43:201–267.CrossRefGoogle Scholar
  47. 47.
    Canetti G, Grumbach F, Grosset J (1963) Long-term, two-stage chemotherapy of advanced experimental murine tuberculosis with intermittent regimes during the second stage. Tubercle 44:236–240.PubMedCrossRefGoogle Scholar
  48. 48.
    Crofton J (1963) Etude comparative des résultats obtenus par l’emploi de la streptomycine quotidiennement, et par son emploi discontinu. Bull Union Int Tuberc 33:51–61.Google Scholar
  49. 49.
    Grumbach F (1962) Treatment of experimental murine tuberculosis with different combinations of isoniazid-streptomycin followed by isoniazid alone. Am Rev Respir Dis 86:211–215.PubMedGoogle Scholar
  50. 50.
    Grumbach F, Rist N (1967) Activité antituberculeuse expérimentale de la rifampicine, dérivé de la rifamycine SV. Rev Tuberc Pneum 31:749–762.Google Scholar
  51. 51.
    Batten J (1970) Rifampicin in the treatment of experimental tuberculosis in mice: sterilization of tubercle bacilli in the tissues. Tubercle 51:95–99.PubMedCrossRefGoogle Scholar
  52. 52.
    Havel A, Adamek L, Simonova S (1970) Rifampicin in experimental investigations on mice. Antibiot Chemother 16:406–415.PubMedGoogle Scholar
  53. 53.
    Verbist L (1969) Rifampicin activity in vitro and in established tuberculosis in mice. Acta Tuberc Pneumol Belg 3–4:397–412.Google Scholar
  54. 54.
    Grumbach F, Canetti G, Le Lirzin M (1969) Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results. Tubercle 50:380–393.CrossRefGoogle Scholar
  55. 55.
    Grumbach F (1969) Experimental in vivo studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin. Tubercle 50(March Suppl): 12–21.PubMedGoogle Scholar
  56. 56.
    Grosset J, Truffot-Pernot Ch, Lecoeur H, Guelpa-Lauras CC (1983) Activité de la rifampicine administrée quotidiennement et d’une manière intermittente sur la tuberculose expérimentale de la souris. Pathol Biol 31:446–450.PubMedGoogle Scholar
  57. 57.
    Canetti G, Le Lirzin M, Porven G, Rist N, Grumbach F (1968) Some comparative aspects of rifampicin and isoniazid. Tubercle 49:367–376.PubMedCrossRefGoogle Scholar
  58. 58.
    Mitchison DA (1985) The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219–225.PubMedCrossRefGoogle Scholar
  59. 59.
    Grumbach F (1975) La durée optimale de l’antibiothérapie par l’association isoniazide + rifampicine dans la tuberculose experimentale de la souris. Etude de la phase postthérapeutique. Epreuve de la cortisone. Rev Fr Mal Respir 3:625–634.Google Scholar
  60. 60.
    Grosset J, Truffot Ch, Fermanian S, Lecoeur H (1982) Activité stérilisante des différents antibiotiques dans la tuberculose expérimentale de la souris. Pathol Biol 30:444–448.PubMedGoogle Scholar
  61. 61.
    World Health Organization Working Group (1991) Tuberculosis Research and Development. WHO/TB/91–162. Geneva: World Health Organization.Google Scholar
  62. 62.
    Culliton BJ (1993) Drug-resistant TB may bring epidemic. Nature (London) 356:473.Google Scholar
  63. 63.
    Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328:521–526.PubMedCrossRefGoogle Scholar
  64. 64.
    Cohn ML, Kovitz C, Oda U, Middlebrook G (1954) Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid resistant mutants. Am Rev Tuberc 70:641–664.PubMedGoogle Scholar
  65. 65.
    Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320:545–550.PubMedCrossRefGoogle Scholar
  66. 66.
    Barnes PF, Bloch AB, Davidson PT, Snider De Jr (1991) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 24:1644–1650.Google Scholar
  67. 67.
    Narain JP, Raviglione MC, Kochi A (1992) HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuberc Lung Dis 73:311–321.CrossRefGoogle Scholar
  68. 68.
    Yangco BG, Lackman-Smith C, Espinoza CG, Solomon DA, and Deresinski SC (1989) The hamster model of chronic Mycobacterium avium complex infection. J Infect Dis 159:556–561.PubMedCrossRefGoogle Scholar
  69. 69.
    Collins FM, Stokes RW (1987) Mycobacterium avium-complex infections in normal and immunodeficient mice. Tubercle 68:127–136.PubMedCrossRefGoogle Scholar
  70. 70.
    Kuze F (1984) Experimental chemotherapy in chronic Mycobacterium avium— intracellulare infection of mice. Am Rev Respir Dis 129:453–459.PubMedGoogle Scholar
  71. 71.
    Furney SK, Skinner PS, Farrer J, Orme IM (1995) Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. Actimicrob Agents Chemother 39:786–789.CrossRefGoogle Scholar
  72. 72.
    Cohen Y, Perronne C, Lazard T, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ (1995) Use of normal C57BL/6 mice with established Mycobacterium avium infection as an alternative model for evaluation of antibiotic activity. Antimicrob Agents Chemother 39:735–738.PubMedCrossRefGoogle Scholar
  73. 73.
    Ji B, Lounis N, Truffot-Pernot C, Grosset J (1991) Susceptibility of the immunocompetent, beige and nude mice to Mycobacterium avium complex infection and response to clarithromycin. Program Abstracts 31 st Interscience Conference on Antimicrobial Agent Chemotherapy.Google Scholar
  74. 74.
    Furney SK, Roberts AD, Orme IM (1990) Effect of rifabutin on disseminated Mycobacterium avium infection ib thymectomized CD4 T-cell-deficient mice. Antimicrob Agents Chemother 34:1629–1632.PubMedCrossRefGoogle Scholar
  75. 75.
    Gangadharam PRJ, Edwards CK, Murthy PS, Pratt PF (1983) An acute infection model for Mycobacterium intracellulare disease using beige mice. Preliminary results. Am Rev Respir Dis 127:468–469.Google Scholar
  76. 76.
    Betram MA, Inderlied CB, Yadegar S, Kolanoski P, Yamada JP, Young LS (1986) Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis 154:194–195.CrossRefGoogle Scholar
  77. 77.
    Ji B, Lounis N, Truffot-Pernot C, Grosset J (1994) Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 38:2521–2529.PubMedCrossRefGoogle Scholar
  78. 78.
    Gangadharam PRJ (1986) Animal models for nontuberculosis mycobacterial diseases. In: Zak O, Sande MA, eds. Experimental Models in Antimicrobial Chemotherapy. Volume 3, pp. 1–94. London: Academic Press.Google Scholar
  79. 79.
    Roder JC (1979) The beige mutation in the mouse. J Immunol 123:2168–2173.PubMedGoogle Scholar
  80. 80.
    Winn WA, Petroff SA (1933) Biological studies of the tubercle bacilli. II. A new conception of the pathology of experimental avium tuberculosis with special reference to the disease produced by dissociated variants. J Exp Med 57:239–270.PubMedCrossRefGoogle Scholar
  81. 81.
    Moehring JM, Solotorowsky MR (1965) Relationship of colonial morphology to virulence to chickens of Mycobacterium avium and the nonphotochromogens. Am Rev Respir Dis 92:704–713.PubMedGoogle Scholar
  82. 82.
    Schaefer WB, Davis CL, Cohn ML (1970) Pathogenicity of transparent, opaque, and rough variants of Mycobacterium avium in chickens and mice. Am Rev Respir Dis 102:499–506.PubMedGoogle Scholar
  83. 83.
    Woodley CL, David HL (1976) Effect of temperature on the rate of the transparent to opaque colony type transition in Mycobacterium avium. Antimicrob Agents Chemother 9:113–119.PubMedCrossRefGoogle Scholar
  84. 84.
    Saito H, Tomioka H (1988) Susceptibilities of transparent, opaque, and rough colonial variants of Mycobacterium avium complex to various fatty acids. Antimicrob Agents Chemother 32:400–402.PubMedCrossRefGoogle Scholar
  85. 85.
    Gangadharam PRJ, Perumal VX, Jairam BT, Rao PN, Nguyen AK, Farhi DC, Iseman MD (1987) Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis 136:329–333.PubMedCrossRefGoogle Scholar
  86. 86.
    Gangadharam PRJ, Perumal VX, Podapati NR, Kesavalu L, Iseman MD (1988) In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 32:1400–1403.PubMedCrossRefGoogle Scholar
  87. 87.
    Inderlied CB, Kolonoski PT, Wu M, Young LS (1989) Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. Antimicrob Agents Chemother 33:176–180.PubMedCrossRefGoogle Scholar
  88. 88.
    Fernandes PR, Hardy DJ, McDaniel D, Hanson CW, Swanson RN (1989) In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 33:1531–1534.PubMedCrossRefGoogle Scholar
  89. 89.
    Klemens SP, Cynamon MH (1991) In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother 35:2026— 2030.PubMedCrossRefGoogle Scholar
  90. 90.
    Cynamon MH, Klemens SP (1992) Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 36:1611–1613.PubMedCrossRefGoogle Scholar
  91. 91.
    Klemens SP, Cynamon MH (1992) Activity of rifapentine against Mycobacterium avium infection in beige mice. J Antimicrob Chemother 29:555–561.PubMedCrossRefGoogle Scholar
  92. 92.
    Kolonoski PT, Wu M, Inderlied CB, Young LS (1992) Azithromycin (AZM), ethambutol (EMB) and sparfloxacin (SP) for disseminated M. avium complex (MAC) infection in C57 beige mice. Program Abstracts 32nd Interscience Conference on Antimicrobial Agents Chemotherapy.Google Scholar
  93. 93.
    Ji B, Lounis N, Truffot-Pernot C, Grosset J (1992) Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother 36:2839–2840.PubMedCrossRefGoogle Scholar
  94. 94.
    Lounis N, Ji B, Truffot-Pernot C, Grosset J (1995) Selection of clarithromycinresistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob Agents Chemother 39:608–612.PubMedCrossRefGoogle Scholar
  95. 95.
    Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro activities of clarithromycincontaining double- or triple-drug combinations against Mycobacterium avium complex. Program Abstracts First International Conference on Macrolides, Azalides and Streptogramins.Google Scholar
  96. 96.
    Klemens S, DeStefano MS, Cynamon MH (1992) Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 36:2413–2417.PubMedCrossRefGoogle Scholar
  97. 97.
    Dautzenberg B, Truffot C, Legris S, Meyohas M, Berlie HC, Mercat A, Chevret S, Grosset J (1991) Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 144:564–569.PubMedCrossRefGoogle Scholar
  98. 98.
    Dautzenberg B, Saintmarc T, Meyohas MC, Eliaszewitch M, Haniez F, Rogues AM, Dewit S, Cotte L, Chauvin JP, Grosset J (1993) Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 153:368–372.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • Jacques Grosset
  • Baohong Ji

There are no affiliations available

Personalised recommendations